XML 54 R30.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaborative Arrangements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Collaborative Arrangements [Abstract] |
Schedule of Collaborative Arrangements | Summarized financial information related to this collaboration is as follows:
Years Ended December 31 | 2020 |  | 2019 |  | 2018
Alliance revenue - Lynparza | $ | 725 |  |  | $ | 444 |  |  | $ | 187 |
Alliance revenue - Koselugo | 8 |  |  | — |  |  | — |
Total alliance revenue | $ | 733 |  |  | $ | 444 |  |  | $ | 187 |
Cost of sales (1) | 247 |  |  | 148 |  |  | 93 |
Selling, general and administrative | 160 |  |  | 138 |  |  | 48 |
Research and development | 133 |  |  | 168 |  |  | 152 |
December 31 | 2020 |  | 2019 |  |
Receivables from AstraZeneca included in Other current assets | $ | 215 |  |  | $ | 128 |  |  |
Payables to AstraZeneca included in Accrued and other current liabilities (2) | 423 |  |  | 577 |  |  |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
Years Ended December 31 | 2020 |  | 2019 |  | 2018
Alliance revenue - Lenvima | $ | 580 |  |  | $ | 404 |  |  | $ | 149 |
Cost of sales (1) | 271 |  |  | 206 |  |  | 39 |
Selling, general and administrative | 73 |  |  | 80 |  |  | 13 |
Research and development (2) | 185 |  |  | 189 |  |  | 1,489 |
December 31 | 2020 |  | 2019 |  |
Receivables from Eisai included in Other current assets | $ | 157 |  |  | $ | 150 |  |  |
Payables to Eisai included in Accrued and other current liabilities (3) | 335 |  |  | 700 |  |  |
Payables to Eisai included in Other Noncurrent Liabilities (4) | 600 |  |  | 525 |  |  |
(1) Represents amortization of capitalized milestone payments. (2) Amount for 2018 includes $1.4 billion related to the upfront payment and option payments. (3) Includes accrued milestone and future option payments. (4) Includes accrued milestone payments. Summarized financial information related to this collaboration is as follows:
Years Ended December 31 | 2020 |  | 2019 |  | 2018
Alliance revenue - Adempas | $ | 281 |  |  | $ | 204 |  |  | $ | 139 |
Net sales of Adempas recorded by Merck | 220 |  |  | 215 |  |  | 190 |
Total sales | $ | 501 |  |  | $ | 419 |  |  | $ | 329 |
Cost of sales (1) | 115 |  |  | 113 |  |  | 216 |
Selling, general and administrative | 61 |  |  | 41 |  |  | 35 |
Research and development | 63 |  |  | 126 |  |  | 127 |
December 31 | 2020 |  | 2019 |  |
Receivables from Bayer included in Other current assets | $ | 65 |  |  | $ | 49 |  |  |
Payables to Bayer included in Other Noncurrent Liabilities (2) | — |  |  | 375 |  |  |
(1) Includes amortization of intangible assets. (2) Represents accrued milestone payment.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration